Response of Human Glioblastoma Cells to Vitamin B12 Deficiency: A Study Using the Non-Toxic Cobalamin Antagonist.
antivitamins
cobalamin
cobalamin antagonists
glioblastoma
vitamin B12
vitamin B12 deficiency
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
19 Jan 2021
19 Jan 2021
Historique:
received:
23
12
2020
revised:
11
01
2021
accepted:
15
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
23
1
2021
Statut:
epublish
Résumé
The most important biological function of vitamin B12 is to accomplish DNA synthesis, which is necessary for cell division. Cobalamin deficiency may be especially acute for rapidly dividing cells, such as glioblastoma cells. Therefore, cobalamin antagonists offer a medicinal potential for developing anti-glioma agents. In the present study, we developed an in vitro model of cobalamin deficiency in glioblastoma cells. Long-term treatment of cells with the cobalamin analogue, hydroxycobalamin [
Identifiants
pubmed: 33478021
pii: biology10010069
doi: 10.3390/biology10010069
pmc: PMC7835758
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-2-O41/D/9/N; KNW-1-037/K/9/O
Références
Curr Med Chem. 2017;24(27):3002-3009
pubmed: 28521700
Cell Syst. 2017 Nov 22;5(5):445-459.e5
pubmed: 29102360
Front Oncol. 2017 Mar 30;7:46
pubmed: 28424758
J Clin Invest. 1991 Apr;87(4):1422-30
pubmed: 1672697
Curr Protoc Cytom. 2011 Apr;Chapter 7:Unit 7.2
pubmed: 21455968
Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804
pubmed: 15459660
Integr Med (Encinitas). 2017 Feb;16(1):42-49
pubmed: 28223907
Biochimie. 2013 May;95(5):1008-18
pubmed: 23415653
Methods Mol Biol. 2015;1263:243-50
pubmed: 25618350
Methods Mol Biol. 2019;1866:49-60
pubmed: 30725407
Mutat Res. 2012 May 1;733(1-2):21-33
pubmed: 22093367
J Inherit Metab Dis. 2009 Dec;32(6):720-727
pubmed: 19816787
Neurosci Lett. 2000 Jul 21;288(3):191-4
pubmed: 10889340
Nat Commun. 2016 Jul 14;7:12100
pubmed: 27411955
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21930-5
pubmed: 19959661
Expert Opin Pharmacother. 2010 Feb;11(2):249-56
pubmed: 20088746
Toxicol Sci. 2018 May 1;163(1):5-12
pubmed: 29471431
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
PLoS One. 2017 Jan 30;12(1):e0171026
pubmed: 28135329
Blood. 1990 Oct 1;76(7):1380-6
pubmed: 2169922
Cancer Res. 1956 Jan;16(1):87-94
pubmed: 13284736
Cell Div. 2009 Jul 03;4:13
pubmed: 19575778
Biochem J. 1990 Mar 15;266(3):809-15
pubmed: 2327967
Cell Death Dis. 2013 Mar 21;4:e553
pubmed: 23519122
Toxicology. 2015 Oct 2;336:48-58
pubmed: 26219506
PLoS One. 2014 May 21;9(5):e97888
pubmed: 24847863
Neuro Oncol. 2016 Jan;18(1):27-36
pubmed: 26359209
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Chembiochem. 2015 Jun 15;16(9):1264-78
pubmed: 26013037
Cells. 2019 Nov 24;8(12):
pubmed: 31771278
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
Biochim Biophys Acta. 1995 Oct 19;1269(1):6-12
pubmed: 7578272
Int J Mol Sci. 2018 Sep 19;19(9):
pubmed: 30235895
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4095-E4102
pubmed: 28461497
Cancers (Basel). 2020 Oct 04;12(10):
pubmed: 33020459
Regul Toxicol Pharmacol. 2014 Aug;69(3):496-511
pubmed: 24874798
Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):165-72
pubmed: 16945824
Anticancer Res. 2013 Oct;33(10):4203-12
pubmed: 24122983
Nat Rev Dis Primers. 2017 Jun 29;3:17040
pubmed: 28660890
Front Mol Biosci. 2016 Jun 27;3:27
pubmed: 27446930